Michael Green, MD
Multiple myeloma is a heterogeneous disease requiring diverse and individualized therapies for patients who experience early relapse, explained Michael Green, MD, adding that physicians fortunately have a number of regimens to choose from in this setting.
“There are a variety of treatment options for early relapse in multiple myeloma,” said Green. “We have to take into account patient preference, patient comorbidities, prior therapies, the pace of the relapse, and biological determinants of health. By doing that, we can construct a treatment strategy that improves people's lives.”
There is no standard first-line therapy for those who relapse early, but Green pointed to the triplet of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone as having impressive efficacy.
... to read the full story